Axsome Therapeutics AXSM Other Current Liabilities
Other Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Axsome Therapeutics's other current liabilities?
- Axsome Therapeutics (AXSM) reported other current liabilities of $17.23M in Q1 2026.
- How has Axsome Therapeutics's other current liabilities changed year-over-year?
- Axsome Therapeutics's other current liabilities increased by 2006.2% year-over-year, from $818K to $17.23M.
- What is the long-term trend for Axsome Therapeutics's other current liabilities?
- Over 3 years (2022 to 2025), Axsome Therapeutics's other current liabilities has grown at a 24.0% compound annual growth rate (CAGR), from $43.92M to $83.74M.